Thermo Fisher Scientific Inc. announced that WIL Research Company, Inc., a global contract-research organization (CRO) providing analytical services to the pharmaceutical industry, selected Thermo Scientific Q Exactive hybrid quadrupole-Orbitrap mass spectrometer systems to expand its capabilities for regulated bioanalysis, drug discovery, metabolism, and structural identification services.
The systems were validated for GLP compliance using Thermo Fisher Scientific Validation Support Services. These services dramatically reduce the overall validation burden by providing test scripts specifically customized for WIL Research’s standard operating procedures and system requirements.
“The Q Exactive system offers greater flexibility and simpler operation than our triple quadrupole mass spectrometer systems, and will be extremely effective in addressing our most challenging analytical projects,” said Dr.Terry Johnson, Director of Metabolism, WIL Research. “The system’s versatility, ruggedness and sensitivity make it very well suited to qualitative drug metabolism, as well as quantitative studies.”
The Q Exactive system’s unique HR/AM capability will expand the analytical capabilities that WIL Research can provide to its customers. The Q Exactive system is the first commercially available mass spectrometer to bring together quadrupole precursor selection and high-resolution, accurate-mass Orbitrap mass analysis to deliver high-confidence quantitative and qualitative (quan/qual) workflows. With innovative HR/AM Quanfirmation capability, the Q Exactive mass spectrometer makes it possible to identify, quantify and confirm more trace-level drugs, metabolites, peptides and proteins in complex mixtures. Unlike other HR/AM technologies, high-confidence results are obtained without sacrificing quantitative LLOQ’s, reproducibility or mass resolution.
Date: June 26, 2012
Source: Thermo Fisher Scientific Inc.
Filed Under: Drug Discovery
